Altered expression of MLL methyltransferase family genes in breast cancer

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 653-660

  Do Amaral Rabello, Doralina ^a   De Moura, Carolina Amaro ^a   De Andrade, Rosangela Vieira ^b   Motoyama, Andrea Barretto ^a   Silva, Fabio Pittella ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

Author keywords

Breast cancer; Gene expression. MLL (ALL 1), MLL2, MLL3, MLL4 and MLL5

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN 2; MIXED LINEAGE LEUKEMIA PROTEIN 3; MIXED LINEAGE LEUKEMIA PROTEIN 4; MIXED LINEAGE LEUKEMIA PROTEIN 5; UNCLASSIFIED DRUG;

ARTICLE; BRAIN; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN FUNCTION; SKELETAL MUSCLE;

BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; METHYLTRANSFERASES; NEOPLASM PROTEINS;

EID: 84879614664     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1981     Document Type: Article

References (40)

1. IARC: World Cancer Report. IARC, Lyon, 2008.
2. INCA: Estimativa 2012: Incidência de câncer no Brasil. INCA Rio de Janeiro, 2011 (In Portuguese).
3. Castro N, Osório C, Torres C, et al: Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 10: R87, 2008.
4. Tamimi R, Baer H, Marotti J, et al: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10: R67, 2008.
5. Sjöblom T, Jones S, Wood L, et al: The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274, 2006.
6. Deng L-W, Chiu I and Strominger J: MLL 5 protein forms intranuclear foci and overexpression inhibits cell cycle progression. Proc Natl Acad Sci USA 101: 757-762, 2004. (Pubitemid 38121031)
7. Ayton P and Cleary M: Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20: 5695-5707, 2001. (Pubitemid 32928107)
8. Yu B, Hess J, Horning S, Brown G and Korsmeyer S: Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378: 505-508, 1995.
9. McKinnell I, Ishibashi J, Le Grand F, et al: Pax7 activates myogenic genes by recruitment of a histone methyltransferase complex. Nat Cell Biol 10: 77-84, 2008.
10. Aziz A, Liu Q-C and Dilworth F: Regulating a master regulator: establishing tissue-specific gene expression in skeletal muscle. Epigenetics 5: 691-695, 2010.
11. Ruault M, Brun M, Ventura M, Roizès G and De Sario A: MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia. Gene 284: 73-81, 2002. (Pubitemid 34219402)
12. Lee J, Kim D-H, Lee S, et al: A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci USA 106: 8513-8518, 2009.
13. Glaser S, Schaft J, Lubitz S, et al: Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 133: 1423-1432, 2006. (Pubitemid 43732956)
14. Emerling B, Bonifas J, Kratz C, et al: MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene 21: 4849-4854, 2002. (Pubitemid 34879461)
15. Sebastian S, Sreenivas P, Sambasivan R, et al: MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression and promotes myogenic differentiation. Proc Natl Acad Sci USA 106: 4719-4724, 2009.
16. Madan V, Madan B, Brykczynska U, et al: Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. Blood 113: 1444-1454, 2009.
17. Ansari K, Kasiri S, Hussain I and Mandal S: Mixed lineage leukemia histone methylases play critical roles in estrogen-mediated regulation of HOXC13. FEBS J 276: 7400-7411, 2009.
18. Mo R, Rao S and Zhu Y-J: Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem 281: 15714-15720, 2006. (Pubitemid 43848459)
19. Ansari K, Hussain I, Kasiri S and Mandal S: HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4. J Mol Endocrinol 48: 61-75, 2012.
20. Neve R, Chin K, Fridlyand J, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527, 2006. (Pubitemid 44854747)
21. Finak G, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527, 2008. (Pubitemid 351655218)
22. Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007. (Pubitemid 47525152)
23. Sims R, Nishioka K and Reinberg D: Histone lysine methylation: a signature for chromatin function. Trends Genet 19: 629-639, 2003. (Pubitemid 37338383)
24. Miremadi A, Oestergaard M, Pharoah P and Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet 16: R28-R49, 2007. (Pubitemid 47241841)
25. Hamamoto R, Silva F, Tsuge M, et al: Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97: 113-118, 2006. (Pubitemid 43379478)
26. Chang CJ and Hung MC: The role of EZH2 in tumour progression. Br J Cancer 106: 243-247, 2012.
27. Al Sarakbi W, Sasi W, Jiang W, Roberts T, Newbold R and Mokbel K: The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer 9: 290, 2009.
28. Nishikawa N, Toyota M, Suzuki H, et al: Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 67: 9649-9657, 2007. (Pubitemid 47621211)
29. Canaani E, Nakamura T, Rozovskaia T, et al: ALL-1/MLL1, a homologue of Drosophila trithorax, modifies chromatin and is directly involved in infant acute leukaemia. Br J Cancer 90: 756-760, 2004. (Pubitemid 38406582)
30. Patani N, Jiang W, Newbold R and Mokbel K: Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res 31: 4115-4125, 2011.
31. Liu H, Takeda S, Kumar R, et al: Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467: 343-346, 2010.
32. Huntsman D, Chin S, Muleris M, et al: MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene 18: 7975-7984, 1999. (Pubitemid 30050558)
33. Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303, 2011.
34. Pasqualucci L, Trifonov V, Fabbri G, et al: Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43: 830-837, 2011.
35. Dalgliesh G, Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363, 2010.
36. Guo C, Chang CC, Wortham M, et al: Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci USA 109: 17603-17608, 2012.
37. Wang X-X, Fu L, Li X, et al: Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol Oncol Res 17: 429-433, 2011.
38. Parsons D, Li M, Zhang X, et al: The genetic landscape of the childhood cancer medulloblastoma. Science 331: 435-439, 2011.
39. Watanabe Y, Castoro R, Kim H, et al: Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One 6: e23320, 2011.
40. Damm F, Oberacker T, Thol F, et al: Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol 29: 682-689, 2011. University of Brasilia